SG11201408770RA - Compounds and therapeutic uses thereof - Google Patents
Compounds and therapeutic uses thereofInfo
- Publication number
- SG11201408770RA SG11201408770RA SG11201408770RA SG11201408770RA SG11201408770RA SG 11201408770R A SG11201408770R A SG 11201408770RA SG 11201408770R A SG11201408770R A SG 11201408770RA SG 11201408770R A SG11201408770R A SG 11201408770RA SG 11201408770R A SG11201408770R A SG 11201408770RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cmpd
- bid
- utah
- parent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/58—Amidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665297P | 2012-06-27 | 2012-06-27 | |
| PCT/US2013/048274 WO2014004884A1 (en) | 2012-06-27 | 2013-06-27 | Compounds and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408770RA true SG11201408770RA (en) | 2015-01-29 |
Family
ID=49783870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408770RA SG11201408770RA (en) | 2012-06-27 | 2013-06-27 | Compounds and therapeutic uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150344426A1 (zh) |
| EP (1) | EP2867209A4 (zh) |
| JP (1) | JP2015522028A (zh) |
| KR (1) | KR20150024932A (zh) |
| CN (1) | CN104768931A (zh) |
| AU (1) | AU2013284487A1 (zh) |
| BR (1) | BR112014032917A2 (zh) |
| CL (1) | CL2014003560A1 (zh) |
| IL (1) | IL236499A0 (zh) |
| IN (1) | IN2015KN00240A (zh) |
| MA (1) | MA37808A1 (zh) |
| MX (1) | MX2015000101A (zh) |
| PH (1) | PH12015500179A1 (zh) |
| RU (1) | RU2015102278A (zh) |
| SG (1) | SG11201408770RA (zh) |
| WO (1) | WO2014004884A1 (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3131881A4 (en) | 2014-04-18 | 2017-09-06 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
| JP2017520526A (ja) * | 2014-05-22 | 2017-07-27 | ザ・ユニバーシティ・オブ・シドニー | オメガ−３類似体 |
| CA2974078A1 (en) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof |
| EP3594343B1 (en) * | 2015-07-23 | 2021-04-21 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| FR3047552A1 (fr) * | 2016-02-05 | 2017-08-11 | Air Liquide | Introduction optimisee d'un courant refrigerant mixte diphasique dans un procede de liquefaction de gaz naturel |
| WO2017170826A1 (ja) * | 2016-03-30 | 2017-10-05 | 味の素株式会社 | グルカゴン様ペプチド－１受容体作用増強活性を有する化合物 |
| KR101869794B1 (ko) * | 2016-07-20 | 2018-06-21 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
| US10683387B2 (en) | 2016-10-04 | 2020-06-16 | Massachusetts Institute Of Technology | Bottlebrush copolymers and uses thereof |
| WO2019006425A1 (en) | 2017-06-30 | 2019-01-03 | Massachusetts Institute Of Technology | IMAGING AGENTS OF BRUSH ARRAY STAR POLYMERS AND USES THEREOF |
| JP7187048B2 (ja) | 2017-06-30 | 2022-12-12 | マサチューセッツ インスティテュート オブ テクノロジー | 分枝多官能性マクロモノマーおよび関連ポリマーならびにそれらの使用 |
| KR101937126B1 (ko) * | 2018-06-15 | 2019-01-10 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
| WO2020037236A1 (en) | 2018-08-17 | 2020-02-20 | Massachusetts Institute Of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
| EP3870166A4 (en) * | 2018-10-22 | 2022-09-28 | Yale University | IDENTIFICATION OF PPM1D MUTATIONS AS NOVEL BIOMARKERS OF NAMPTI SENSITIVITY |
| EP4045562A2 (en) * | 2019-10-16 | 2022-08-24 | Massachusetts Institute of Technology | Brush prodrugs and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
| US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| CA2485351C (en) * | 2002-05-17 | 2011-12-06 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| JP5688367B2 (ja) * | 2008-08-29 | 2015-03-25 | トポターゲット・アクティーゼルスカブＴｏｐｏＴａｒｇｅｔ Ａ／Ｓ | 新規なウレアおよびチオウレア誘導体 |
| NZ601788A (en) * | 2010-03-01 | 2014-11-28 | Myrexis Inc | Inhibitors of nicotinamide phosphoribosyltransferase and therapeutic uses thereof |
| TW201217359A (en) * | 2010-09-03 | 2012-05-01 | Forma Therapeutics Inc | Novel compounds and compositions for the inhibition of NAMPT |
-
2013
- 2013-06-27 MA MA37808A patent/MA37808A1/fr unknown
- 2013-06-27 RU RU2015102278A patent/RU2015102278A/ru not_active Application Discontinuation
- 2013-06-27 BR BR112014032917A patent/BR112014032917A2/pt not_active IP Right Cessation
- 2013-06-27 KR KR20157002268A patent/KR20150024932A/ko not_active Application Discontinuation
- 2013-06-27 WO PCT/US2013/048274 patent/WO2014004884A1/en active Application Filing
- 2013-06-27 JP JP2015520521A patent/JP2015522028A/ja active Pending
- 2013-06-27 IN IN240KON2015 patent/IN2015KN00240A/en unknown
- 2013-06-27 EP EP13810056.5A patent/EP2867209A4/en not_active Withdrawn
- 2013-06-27 MX MX2015000101A patent/MX2015000101A/es unknown
- 2013-06-27 CN CN201380045302.4A patent/CN104768931A/zh active Pending
- 2013-06-27 SG SG11201408770RA patent/SG11201408770RA/en unknown
- 2013-06-27 AU AU2013284487A patent/AU2013284487A1/en not_active Abandoned
-
2014
- 2014-12-24 US US14/582,641 patent/US20150344426A1/en not_active Abandoned
- 2014-12-28 IL IL236499A patent/IL236499A0/en unknown
- 2014-12-29 CL CL2014003560A patent/CL2014003560A1/es unknown
-
2015
- 2015-01-27 PH PH12015500179A patent/PH12015500179A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2867209A4 (en) | 2015-11-25 |
| BR112014032917A2 (pt) | 2017-06-27 |
| RU2015102278A (ru) | 2016-08-20 |
| JP2015522028A (ja) | 2015-08-03 |
| IN2015KN00240A (zh) | 2015-06-12 |
| WO2014004884A1 (en) | 2014-01-03 |
| KR20150024932A (ko) | 2015-03-09 |
| MX2015000101A (es) | 2015-06-22 |
| AU2013284487A1 (en) | 2015-02-19 |
| MA37808A1 (fr) | 2018-03-30 |
| CN104768931A (zh) | 2015-07-08 |
| IL236499A0 (en) | 2015-02-26 |
| EP2867209A1 (en) | 2015-05-06 |
| CL2014003560A1 (es) | 2015-11-27 |
| PH12015500179A1 (en) | 2015-04-06 |
| US20150344426A1 (en) | 2015-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408770RA (en) | Compounds and therapeutic uses thereof | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201408614SA (en) | Flexible assembly machine, system and method | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
| SG11201408261UA (en) | Syringe | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201407349UA (en) | Proliposomal testosterone formulations | |
| SG11201407898WA (en) | Electrode testing apparatus | |
| SG11201407200TA (en) | Liquid formulation |